ImmuPharma enter into agreements with two specialist US healthcare investors for a total investment of up to $6.30 million

ImmuPharma PLC (LON:IMM, the specialist drug discovery and development company, has announced that it has entered into agreements with two specialist US healthcare investors for a total investment of up to $6.30 million (£4.94 million) comprising an issue of unsecured convertible securities and associated options.

Highlights

·    ImmuPharma is to issue $3 million (£2.35 million) in face value of Securities to two US specialist healthcare investors, L1 Capital Global Opportunities Master Fund and Lind Global Macro Fund LP, managed by The Lind Partners, LLC (“the Investors”) with a maturity period of 18 months.

·    At any time, during the maturity period, the Investors may convert their Securities (in whole or in part) to 13,086,619 ordinary shares in the Company, in aggregate, at a price of 17.96p (“Conversion Price”) which is equivalent to 120% of the Volume Weighted Average Price (“VWAP”) of the ordinary shares for 09 June 2020.

·    During the maturity period, the Company may require the investors to convert their securities to ordinary shares, if the VWAP on each of at least 20 consecutive trading days shall be equal to or have exceeded 35.92p (200% of the Conversion Price).

·    Should any securities remain unconverted on 10 December 2021  the Company will repurchase, from the Investors, the outstanding face value of the unconverted Securities.

·    In addition, the Investors have been granted 15,703,942 Options in the Company, which may be exercised at any time up to 3 years,  with an exercise price the same as the Conversion Price, which, if all exercised, would amount to $3.60 million (£2.82 million).

·    The initial net proceeds of the Securities (after subscription and expenses) received by the Company of $2.39 million (£1.87 million) and any additional funds received of up to $3.60 million (£2.82 million), following exercise of the Options, will be used primarily to fund:

  • Continued expansion of the Company’s R&D programmes; and
  • General working capital.

Commenting, ImmuPharma’s Chairman, Tim McCarthy, said:

“We are delighted to welcome L1 Capital Global Opportunities Master Fund and Lind Global Macro Fund LP as new investors into ImmuPharma. This is the first significant investment from specialist US healthcare funds and illustrates the attention we are now receiving from knowledgeable global investors. It particularly exemplifies the strengthened investment thesis of ImmuPharma, as we continue to strengthen and progress our recently expanded development pipeline to value inflexion points, including Lupuzor™ and the partnership with  Avion Pharmaceuticals, as we prepare for the start of a new international optimised Phase III trial, in lupus patients”

Click to view all articles for the EPIC:
Or click to view the full company profile:
    Facebook
    Twitter
    LinkedIn
    Immupharma Plc

    More articles like this

    Immupharma Plc

    ImmuPharma Major Opportunity Within Lupuzor Unlocked

    ImmuPharma (LON:IMM) announced a major US licensing deal on 28 November 2019 with Avion Pharmaceuticals, a US specialty business that has a focus on Rheumatology, Women’s health (Lupus afflicts women more) Dermatology and other therapeutic areas.

    Immupharma Plc

    ImmuPharma licenses lupus drug Lupuzor

    British pharmaceutical firm ImmuPharma said on Thursday it had signed a licensing and development agreement for Lupuzor, a first-in-class treatment for auto-immune disease Lupus, with U.S. company Avion Pharmaceuticals. Avion and ImmuPharma will co-develop Lupuzor, including

    Immupharma Plc

    ImmuPharma Chairman explains why the Avion deal is so significant

    ImmuPharma plc (LON: IMM) Non-Executive Chairman Tim McCarthy joins DirectorsTalk to discuss a licencing and development agreement with US speciality pharmaceutical company Avion. Tim talks us through the key highlights of the deal, provides background on Avion,

    Immupharma Plc

    ImmuPharma to present at Biotech Showcase™ 2020

    ImmuPharma (LON:IMM), a specialist drug discovery and development company, has announced that it will be presenting at the Biotech Showcase™ 2020, to be held between 13-15 January 2020, at the Hilton, San Francisco Union Square. Dr

    Immupharma Plc

    Selena Gomez’s Lupus Flare Up at AMA’s

    Selena Gomez took to the American Music Awards (AMAs) stage for the first time in two years on Sunday night to perform two new tracks, ‘Lose You To Love Me’ and ‘Look At Her Now’. However, the

    Immupharma Plc

    Selena Gomez opens up on body-shaming comments

    Selena Gomez has admitted to struggling after being “attacked” for gaining weight following her lupus diagnosis. The chart-topping singer, 27, was diagnosed with lupus in 2015 and later underwent a kidney transplant due to complications from

    Immupharma Plc

    Lupus flare-ups could be linked to environmental factors

    Researchers have found that alteration in the environment and atomospheric factors could be associated with organ specific flare-ups of lupus among patients diagnosed with Systemic Lupus Erythematosus (SLE). The study results were presented at the 2019 ACR/ARP Annual Meeting.

    Immupharma Plc

    Lupus: the ‘invisible’ disease

    “Lupus mimics other diseases in your body and the community still doesn’t understand what it is,” says Daniella Djan who is living with the condition. Djan’s life changed irrevocably when she was 18-years-old and diagnosed with

    Immupharma Plc

    Managing Fatigue in Lupus

    Fatigue can be described as a feeling of weariness that is more extreme than simple tiredness. It often includes a lack of both physical and mental (or emotional) energy and motivation. The fatigue that many patients

    Immupharma Plc

    Look At Her Now: Selena Gomez

    Selena Gomez is back, and fans couldn’t be happier. It’s a triumphant return for Selena, who has suffered through health issues and break-ups over the past two years – but nothing can hold this girl down.

    Immupharma Plc

    Living with Lupus

    Another day, another torment. The same will follow the next day — the excruciating pain, inexplicable fatigue, and never-ending drowsiness. This is life with lupus, a rare, chronic autoimmune condition where the body’s immune system starts

    Immupharma Plc

    Lupus: 9 Early Signs that Mean You Have It

    Lupus is a serious disease which causes intense inflammation along with a variety of other symptoms. Each sufferer’s symptoms are quite different. Here, MusicSnake Magazine put together a list of 9 Early Signs that may mean you have lupus. Number One:

    Immupharma Plc

    Lupus and Celiac Disease: What Pharmacists Need to Know

    According to the Lupus Foundation of America, approximately 5 million people globally are affected by lupus and about 16,000 new cases are reported annually. Lupus occurs when the body’s immune system attacks the tissues and organs, which